NMDA antagonists

Claim 1

A compound of the formulae: ##STR15## in which R is represented by hydrogen, C 1-4 alkyl, or --CF 3 ; R 1 and R 2 are each independently represented by hydrogen, C 1-4 alkyl, C 5-6 cycloalkyl, C 1-3 alkylphenyl in which the phenyl ring may be optionally substituted, --CF 3 , phenyl or substituted phenyl; M is represented by N--O--R 3 or N--NH--R 3 , in which R 3 is represented by hydrogen, C 1-4 alkyl or C 1-3 alkylphenyl in which the phenyl ring may be optionally substituted; A is represented by a methylene or a trimethylene bridging group, either of which may be optionally substituted with up to 2 substituents selected from the group consisting of --CF 3 C 1-4 alkyl, C 5-6 cycloalkyl, C 1-3 alkylphenyl in which the phenyl ring may be optionally substituted, phenyl, substituted phenyl; and B is represented by: ##STR16## in which Z is represented by hydrogen, C 1-4 alkyl, C 5-6 cycloalkyl, C 2-4 trialkylamino, C 1-3 alkylphenyl in which the phenyl ring may be optionally substituted, phenyl, or substituted phenyl; the pharmaceutically acceptable acid addition salts thereof; the pharmaceutically acceptable basic addition salts thereof, the optical isomers thereof; the geometric isomers thereof and tautomers thereof, with the following proviso's a) at least one the substituents represented by R, R 1 and R 2 must be a hydrogen atom, and b) when B is represented by a piperazine derivative then at least one of the substituents represented by an oxazolone derivative then R must be a hydrogen atom.